|
Demographic and Clinicopathologic Factors in Melanoma Patients Undergoing Inguino-femoral Lymph Node Dissection (ILND) |
|||||
| Fibrin sealant group, n = 16 |
Control group, n = 14 |
||||
|
|
|
||||
| Variable |
No.a |
% of total |
No.a |
% of total |
P value |
|
|
|||||
| Median age, years (range) |
52 (38–91) |
60 (18–73) |
0.79 |
||
| Sex, male/female |
12/4 |
75/25 |
7/7 |
50/50 |
0.16 |
| Median BMI, kg/m2 (range) |
28.3 (19.6–42.1) |
32.3 (21–48.6) |
0.15 |
||
| Comorbidities |
|||||
| Tobacco use |
1 |
6 |
2 |
14 |
0.58 |
| Diabetes |
1 |
6 |
4 |
29 |
0.16 |
| AJCC tumor stage |
1.00 |
||||
| III |
14 |
88 |
13 |
93 |
|
| IV |
2 |
12 |
1 |
7 |
|
| Melanoma treatment prior to ILND |
|||||
| Surgery |
0.34 |
||||
| None/FNA |
5 |
31 |
4 |
29 |
|
| SLN biopsy |
6 |
38 |
8 |
57 |
|
| Excisional biopsy/WLE |
5 |
31 |
2 |
14 |
|
| Systemic therapy |
0.27 |
||||
| Chemotherapy |
2 |
12 |
0 |
0.48 |
|
| Interferon |
1 |
6 |
2 |
14 |
0.59 |
| Interleukin-2 |
1 |
6 |
0 |
1.00 |
|
|
BMI, body mass index; AJCC, American Joint Committee on Cancer; FNA, fine needle aspiration; SLN, sentinel lymph node; WLE, wide local excision. aData are number of patients unless otherwise indicated. | |||||
Mortenson et al. World Journal of Surgical Oncology 2008 6:63 doi:10.1186/1477-7819-6-63 |
|||||